The road to reimbursement for the new ADC breast cancer drug Troldelvy remains a bumpy one. The agenda remains pending for 8 months now.

Gilead Sciences' triple-negative breast cancer (TNBC) drug Troldelvy, whose reimbursement request received 100,000 consents in a public petition, was not presented for deliberation to the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee in July. The drug’s application has remained without progress since its reimbursement standard was set by the Cancer Disease Review Committee in November last year.

Therefore, attention is now focused on whether the drug will be submitted to DREC in August. Trodelvy is already lis